Sihuan Pharm
About Sihuan
News
Investor Relations
Contact Us
简/繁/EN
Investor Relations/News Release/Details
Investor Relations News2022-01-31

Sihuan 2022 Jan newsletter

Preview
PreviousNew Drug Application of Sihuan Pharmaceutical’s First Self-developed Anti-diabetic Innovation Patented Drug Janagliflozin Accepted by NMPANextSihuan Pharmaceutical Biologics License Application of Three Insulin Aspart Injection Products Developed by Sihuan Pharmaceutical Accepted by Nmpa
Sihuan Pharm
Phone+86 (010) 57693700
Postcode100025
Corporate Address22F, Building 4, Zhubang 2000, Balizhuang Xili, Chaoyang District, Beijing, China

About Sihuan

  • Corporate Overview
  • Brand & Culture
  • History
  • Members
  • Leadership Team
  • Honors
  • ESG

Products

  • Medical Aesthetics
  • Innovative Drugs
  • Mature Medicines
  • Medication Safety

R&D Innovation

  • R&D System
  • Open Collaboration
  • Quality & Safety
  • Commercialization

Investor Relations

  • Disclosure
  • Governance
  • IR Calendar
  • News Release
  • Stock Information
  • IR Contact

Statements & Notices

  • Disclaimer
  • Pharma Reps Registry
WeChat Official Account

WeChat Official Account

Sihuan IR WeChat Account

Sihuan IR WeChat Account

© Sihuan Pharmaceutical Holdings Group Ltd.Hong Kong Stock Exchange Stock Code: 00460.HKBeijing 11011202000890 · Beijing ICP 15000973药监批号 (京)-非经营性-2019-0013